Wall Street believes that novel hair loss treatments are an untapped gold mine, with a large number of consumers willing to pay out of their own pockets to buy better treatment plans. This is reminiscent of the explosive growth experienced by GLP-1 diet pills. The prospect of a novel treatment plan has driven Veradermics's stock price to rise nearly 500% since it went public in February this year; Absci's stock price has also doubled since this year.

Wall Street believes that novel hair loss treatments are an untapped gold mine, with a large number of consumers willing to pay out of their own pockets to buy better treatment plans. This is reminiscent of the explosive growth experienced by GLP-1 diet pills. The prospect of a novel treatment plan has driven Veradermics's stock price to rise nearly 500% since it went public in February this year; Absci's stock price has also doubled since this year.